Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Sumit Aggarwal
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 10
- Beta
- -9.95
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -4.75
Financials
Revenue
$0.00-100.0%Net Income
$-4.50MEBITDA
$-4.45MFree Cash Flow
$-4.79MEPS (diluted)
$-0.66Shares Outstanding (diluted)
6.79M+298587.4%Operating Expenses
$4.45MCash & Debt
$61.96MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-6.00M | $-5.34 |
| 2024 | $6.36M | $-3.14M | $-9.24 |
| 2023 | $0.00 | $-17.05M | $-72.93 |
| 2022 | $0.00 | $-36.06M | $-183.13 |
| 2021 | $0.00 | $-66.73M | $-419.65 |
| 2020 | $0.00 | $-34.58M | $-379.16 |
| 2019 | $0.00 | $-50.87M | $-588.09 |
| 2018 | $0.00 | $-47.19M | $-640.06 |
| 2017 | $0.00 | $-21.21M | $-2090.00 |
| 2015 | $75.0K | $-8.27M | $-3696.00 |
| 2014 | $75.0K | $-18.06M | $-11538.00 |
| 2013 | $100.0K | $-9.23M | $-22264.00 |
| 2012 | $0.00 | $-6.12M | $-44000.00 |
| 2011 | $200.0K | $-5.07M | $-70400.00 |
Valuation
ELOXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
113+40.63%Social Signal Score
Mentions (3)
- Newsbenzinga.com·5h ago·Positive
This Eloxx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
View source ↗ - Newsprnewswire.com·34d ago·Neutral
…rtion of the study expected mid-2027; final readout expected by the end of 2027 ARLINGTON, Mass., Sept. 11, 2026 /PRNewswire/ -- Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today announced that the first two patients have been dosed in the EXACT Study, a Phase 2b clinical trial evaluating exaluren in patients with nonsense mutation Alport syndrome (NMAS).
View source ↗ - Newsprnewswire.com·64d ago·Negative
Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update Completed underwritten public offering with gross proceeds of $66.0 million and uplisting to the Nasdaq Capital Market, significantly strengthening the Company's balance sheet Phase 2b clinical trial of exaluren in nonsense mutation Alport syndrome expected to initiate in the third quarter of 2026 European Commission granted orphan designation for exaluren in ADPKD Cash and cash equivalents of $62.0
View source ↗
Earnings
Wed, Nov 11(in 4 weeks)
Consensus estimate $-0.61 per share
Typical surprise +46.2% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.66 vs $-0.70beat
- Tue, May 5$-0.88 vs $-6.40beat
Estimates and results for ELOX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ELOX officers and directors.
- Bought
- $36k
- Sold
- —
1 trade
0 trades
- Geffken Daniel E.bought
99 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ELOX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.